Chronic inflammatory bowel diseases (IBD) represent some of the most persistent and debilitating challenges in modern gastroenterology. Characterized by a relentless cycle of inflammation, these conditions often defy standard treatments and carry a looming risk of severe complications, including the potential development of colorectal cancer. The burden is particularly heavy for young people, as these diseases frequently manifest during a pivotal stage of life. However, a significant breakthrough from researchers at Charité – Universitätsmedizin Berlin offers new hope. By identifying a specific interaction between two messenger substances in the immune system, the research team has uncovered a therapeutic target that could fundamentally alter the treatment landscape for those most severely affected.
The study, recently published in the prestigious journal Nature Immunology, details how a complex signaling pathway drives the chronic inflammatory processes that define conditions like Crohn’s disease and ulcerative colitis. Led by Professor Ahmed Hegazy and his team at Charité’s Department of Gastroenterology, Infectiology, and Rheumatology, the five-year research project suggests that targeting this pathway could not only alleviate symptoms but also prevent the long-term tissue damage that leads to malignancy.
The Life-Altering Impact of Chronic Inflammation
For many patients, the onset of IBD is a life-altering event. The diseases typically manifest between the ages of 15 and 29—a critical window during which individuals are pursuing higher education, launching careers, and building adult lives. The symptoms are often as unpredictable as they are severe. Patients may experience gradual declines in health or sudden, violent flare-ups characterized by intense abdominal cramping, persistent diarrhea, rapid weight loss, and debilitating fatigue.
Beyond the physical toll, the emotional stress associated with IBD is profound. The necessity for immediate access to facilities and the exhaustion caused by systemic inflammation can lead to social withdrawal and significant psychological strain. While ulcerative colitis is generally confined to the inner lining of the large intestine, Crohn’s disease presents an even more complex challenge, as it can penetrate the entire thickness of the intestinal wall and affect any part of the digestive tract, from the esophagus and stomach to the small intestine.
If left unmanaged, the ongoing inflammation inherent in these diseases causes permanent structural damage to the gut. This chronic state of irritation is a known precursor to cancer, making prompt diagnosis and effective intervention a matter of long-term survival. Traditionally, medical intervention has relied on broad-spectrum immunosuppressants to quiet the body’s overactive defenses. While these treatments are effective for many, they often come with significant side effects and do not work for every patient. Newer, targeted biological therapies have sought to interrupt specific inflammatory markers, yet a substantial portion of the patient population remains "non-responders," leaving clinicians in urgent need of alternative strategies.
Uncontrolled Chain Reaction
The fundamental mystery of IBD lies in its etiology. While genetic predisposition is a known factor, researchers believe environmental influences play a decisive role in triggering the immune system’s self-destructive behavior. Prof. Ahmed Hegazy has spent years investigating these defense mechanisms, specifically focusing on how the gut’s immune environment becomes dysregulated.
"At the clinic, we mainly see young patients who are just beginning their professional lives," Prof. Hegazy explains. "So far, we have only been able to slow down the progression of the disease and alleviate symptoms. But not all patients respond well to existing treatments, so new therapeutic approaches are urgently needed."
The team’s investigation focused on a signaling molecule known as oncostatin M (OSM). Produced by certain immune cells, OSM is a protein that normally plays a role in tissue repair and cell differentiation. However, in the context of IBD, it appears to malfunction, acting instead as a powerful pro-inflammatory catalyst. The researchers observed that OSM triggers a cascade of other inflammatory factors, creating an excessive immune response that the body cannot easily shut down.
A key finding of the research was the correlation between OSM levels and treatment outcomes. "It was especially interesting for us to see that patients with high levels of oncostatin M do not respond to several common therapies," says Prof. Hegazy. This observation suggests that OSM is not just a driver of the disease but also a critical biomarker. High levels of the protein could serve as an early warning sign for clinicians, predicting that a patient is likely to fail standard treatments and may require a more aggressive or specialized approach from the outset.
To understand the mechanics of this "uncontrolled chain reaction," the research team utilized state-of-the-art single-cell sequencing. This technology allowed them to examine the behavior of individual cells within the inflamed tissue with unprecedented precision. By comparing healthy gut tissue with samples from IBD patients, they discovered that inflamed tissue contains a significantly higher number of cells equipped with receptors for oncostatin M. Furthermore, they found that another messenger substance, Interleukin-22 (IL-22), plays a paradoxical role in this process.
IL-22 is generally considered a protective protein; its primary function is to support the cells lining the gut and maintain the integrity of the intestinal barrier. However, the Charité team discovered that in the presence of chronic inflammation, IL-22 actually increases the number of OSM receptors on the gut lining. This makes the tissue hypersensitive to the inflammatory effects of oncostatin M.
"These two immune messengers work together and amplify the inflammation, drawing more immune cells into the intestine, like a fire that keeps getting more fuel and spreads," Prof. Hegazy notes. This synergy explains why the inflammation in some patients becomes so severe and resistant to traditional intervention. When the team used models to specifically block the binding sites for oncostatin M, they observed a dramatic reduction in both the intensity of the chronic inflammation and the associated risk of developing cancer.
Targeted Therapy for High-Risk Patients in Sight
The link between chronic inflammation and colorectal cancer is one of the most concerning aspects of long-term IBD. The research team’s analysis of tissue samples from patients with colitis-associated cancer provided a striking visual confirmation of their theory. They found a high concentration of OSM receptors clustered specifically around tumor sites, whereas the surrounding healthy tissue showed no such accumulation. This suggests that the OSM signaling pathway may directly contribute to the environment that allows tumors to form and grow.
While not every IBD patient will develop cancer, the ability to identify those at the highest risk is a major step toward personalized medicine. The complexity of these diseases has long made them difficult to predict, as the progression varies significantly from one individual to the next.
Prof. Britta Siegmund, Director of the Clinic for Gastroenterology, Infectiology, and Rheumatology at Charité, emphasizes the importance of this discovery for the future of patient care. "Chronic inflammatory bowel diseases are highly complex and differ from person to person. That’s exactly what makes them so difficult to treat and predict treatment," she says. "Thanks to the role of oncostatin M and its amplifying interaction with interleukin-22, which we have now identified, we have a clearer understanding of what drives chronic inflammation in some patients. This opens up the door to developing and testing a new therapeutic approach."
The transition from laboratory findings to clinical application is already underway. Because the research provided a clear scientific basis for how OSM and IL-22 interact to sustain inflammation, the development of targeted antibodies has become a viable path. Currently, a clinical trial is testing an antibody designed to block the receptors for oncostatin M, specifically targeting the mechanism that Prof. Hegazy and his team identified.
This move toward precision medicine represents a shift in how chronic diseases are managed. Rather than attempting to suppress the entire immune system—which can leave patients vulnerable to infections and other complications—future treatments may focus on disrupting the specific "fuel" that drives an individual patient’s inflammatory "fire." For the young people who comprise the majority of new IBD diagnoses, this research offers the potential for a future where their education and careers are no longer sidelined by the unpredictable and destructive nature of their disease.
The findings from Charité – Universitätsmedizin Berlin mark a significant milestone in the five-year journey to decode the molecular drivers of IBD. By illuminating the destructive partnership between IL-22 and oncostatin M, the team has not only provided a new tool for diagnosis but has also paved the way for a generation of therapies that could offer more effective, targeted, and lasting relief for patients worldwide.
